Cargando…

Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B

BACKGROUND: Familial hypercholesterolemia (FH) due to a founder variant in Apolipoprotein B (ApoB(R3500Q)) is reported in 12% of the Pennsylvania Amish community. By studying a cohort of ApoB(R3500Q) heterozygotes and homozygotes, we aimed to characterize the biochemical and cardiac imaging features...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Katie B., Horst, Michael, Young, Millie, Pascua, Christine, Puffenberger, Erik G., Brigatti, Karlla W., Gonzaga-Jauregui, Claudia, Shuldiner, Alan R., Gidding, Samuel, Strauss, Kevin A., Chowdhury, Devyani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928591/
https://www.ncbi.nlm.nih.gov/pubmed/35300601
http://dx.doi.org/10.1186/s12872-022-02539-3
_version_ 1784670674470567936
author Williams, Katie B.
Horst, Michael
Young, Millie
Pascua, Christine
Puffenberger, Erik G.
Brigatti, Karlla W.
Gonzaga-Jauregui, Claudia
Shuldiner, Alan R.
Gidding, Samuel
Strauss, Kevin A.
Chowdhury, Devyani
author_facet Williams, Katie B.
Horst, Michael
Young, Millie
Pascua, Christine
Puffenberger, Erik G.
Brigatti, Karlla W.
Gonzaga-Jauregui, Claudia
Shuldiner, Alan R.
Gidding, Samuel
Strauss, Kevin A.
Chowdhury, Devyani
author_sort Williams, Katie B.
collection PubMed
description BACKGROUND: Familial hypercholesterolemia (FH) due to a founder variant in Apolipoprotein B (ApoB(R3500Q)) is reported in 12% of the Pennsylvania Amish community. By studying a cohort of ApoB(R3500Q) heterozygotes and homozygotes, we aimed to characterize the biochemical and cardiac imaging features in children and young adults with a common genetic background and similar lifestyle. METHODS: We employed advanced lipid profile testing, carotid intima media thickness (CIMT), pulse wave velocity (PWV), and peripheral artery tonometry (PAT) to assess atherosclerosis in a cohort of Amish ApoB(R3500Q) heterozygotes (n = 13), homozygotes (n = 3), and their unaffected, age-matched siblings (n = 9). ApoB(R3500Q) homozygotes were not included in statistical comparisons. RESULTS: LDL cholesterol (LDL-C) was significantly elevated among ApoB(R3500Q) heterozygotes compared to sibling controls, though several ApoB(R3500Q) heterozygotes had LDL-C levels in the normal range. LDL particles (LDL-P), small, dense LDL particles, and ApoB were also significantly elevated among subjects with ApoB(R3500Q). Despite these differences in serum lipids and particles, CIMT and PWV were not significantly different between ApoB(R3500Q) heterozygotes and controls in age-adjusted analysis. CONCLUSIONS: We provide a detailed description of the serum lipids, atherosclerotic plaque burden, vascular stiffness, and endothelial function among children and young adults with FH due to heterozygous ApoB(R3500Q). Fasting LDL-C was lower than what is seen with other forms of FH, and even normal in several ApoB(R3500Q) heterozygotes, emphasizing the importance of cascade genetic testing among related individuals for diagnosis. We found increased number of LDL particles among ApoB(R3500Q) heterozygotes but an absence of detectable atherosclerosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-02539-3.
format Online
Article
Text
id pubmed-8928591
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89285912022-03-23 Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B Williams, Katie B. Horst, Michael Young, Millie Pascua, Christine Puffenberger, Erik G. Brigatti, Karlla W. Gonzaga-Jauregui, Claudia Shuldiner, Alan R. Gidding, Samuel Strauss, Kevin A. Chowdhury, Devyani BMC Cardiovasc Disord Research BACKGROUND: Familial hypercholesterolemia (FH) due to a founder variant in Apolipoprotein B (ApoB(R3500Q)) is reported in 12% of the Pennsylvania Amish community. By studying a cohort of ApoB(R3500Q) heterozygotes and homozygotes, we aimed to characterize the biochemical and cardiac imaging features in children and young adults with a common genetic background and similar lifestyle. METHODS: We employed advanced lipid profile testing, carotid intima media thickness (CIMT), pulse wave velocity (PWV), and peripheral artery tonometry (PAT) to assess atherosclerosis in a cohort of Amish ApoB(R3500Q) heterozygotes (n = 13), homozygotes (n = 3), and their unaffected, age-matched siblings (n = 9). ApoB(R3500Q) homozygotes were not included in statistical comparisons. RESULTS: LDL cholesterol (LDL-C) was significantly elevated among ApoB(R3500Q) heterozygotes compared to sibling controls, though several ApoB(R3500Q) heterozygotes had LDL-C levels in the normal range. LDL particles (LDL-P), small, dense LDL particles, and ApoB were also significantly elevated among subjects with ApoB(R3500Q). Despite these differences in serum lipids and particles, CIMT and PWV were not significantly different between ApoB(R3500Q) heterozygotes and controls in age-adjusted analysis. CONCLUSIONS: We provide a detailed description of the serum lipids, atherosclerotic plaque burden, vascular stiffness, and endothelial function among children and young adults with FH due to heterozygous ApoB(R3500Q). Fasting LDL-C was lower than what is seen with other forms of FH, and even normal in several ApoB(R3500Q) heterozygotes, emphasizing the importance of cascade genetic testing among related individuals for diagnosis. We found increased number of LDL particles among ApoB(R3500Q) heterozygotes but an absence of detectable atherosclerosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-02539-3. BioMed Central 2022-03-17 /pmc/articles/PMC8928591/ /pubmed/35300601 http://dx.doi.org/10.1186/s12872-022-02539-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Williams, Katie B.
Horst, Michael
Young, Millie
Pascua, Christine
Puffenberger, Erik G.
Brigatti, Karlla W.
Gonzaga-Jauregui, Claudia
Shuldiner, Alan R.
Gidding, Samuel
Strauss, Kevin A.
Chowdhury, Devyani
Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B
title Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B
title_full Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B
title_fullStr Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B
title_full_unstemmed Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B
title_short Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B
title_sort clinical characterization of familial hypercholesterolemia due to an amish founder mutation in apolipoprotein b
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928591/
https://www.ncbi.nlm.nih.gov/pubmed/35300601
http://dx.doi.org/10.1186/s12872-022-02539-3
work_keys_str_mv AT williamskatieb clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT horstmichael clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT youngmillie clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT pascuachristine clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT puffenbergererikg clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT brigattikarllaw clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT gonzagajaureguiclaudia clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT shuldineralanr clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT giddingsamuel clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT strausskevina clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb
AT chowdhurydevyani clinicalcharacterizationoffamilialhypercholesterolemiaduetoanamishfoundermutationinapolipoproteinb